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Up to 60% of depressed patients do not respond completely to antidepressants (ADs) and up 
to 30% do not respond at all. Genetic factors contribute for about 50% of the AD response. 
During the recent years the possible influence of a set of candidate genes as genetic predictors 
of AD response efficacy was investigated by us and others. They include the cytochrome 
P450 superfamily, the P-glycoprotein (ABCB1), the tryptophan hydroxylase, the catechol-O-
methyltransferase, the monoamine oxidase A, the serotonin transporter (5-HTTLPR), the 
norepinephrine transporter, the dopamine transporter, variants in the 5-hydroxytryptamine 
receptors (5-HT1A, 5-HT2A, 5-HT3A, 5-HT3B, and 5-HT6), adrenoreceptor beta-1 and alpha-2, 
the dopamine receptors (D2), the G protein beta 3 subunit, the corticotropin releasing hormone 
receptors (CRHR1 and CRHR2), the glucocorticoid receptors, the c-AMP response-element 
binding, and the brain-derived neurotrophic factor. Marginal associations were reported for 
angiotensin I converting enzyme, circadian locomotor output cycles kaput protein, glutamatergic 
system, nitric oxide synthase, and interleukin 1-beta gene. In conclusion, gene variants seem 
to influence human behavior, liability to disorders and treatment response. Nonetheless, 
gene × environment interactions have been hypothesized to modulate several of these 
effects.
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drugs with a better efficacy and safety profiles. ADs currently avail-
able include first- and second-generation drugs. First-generation 
ADs (FGAs) include monoamine oxidase inhibitors (MAOIs) and 
tricyclic ADs (TCAs), which became available for therapy in the 
1960s. The mechanism of MAOIs and TCAs represented the main 
evidence for the monoamine hypothesis of depression and major 
depression (MD), an intrinsically tautological hypothesis which, 
nevertheless, has driven pharmacological research on depression 
for over four decades (Blier and de Montigny, 1994; Stahl, 1998). 
Second-generation ADs (SGAs) include several different classes of 
drugs that were developed mainly in the 1980s and 1990s, starting 
with selective serotonin reuptake inhibitors (SSRIs) and includ-
ing serotonin and noradrenaline reuptake inhibitors (SNRIs), 
noradrenaline reuptake inhibitors (NARIs), noradrenergic and 
specific serotonergic ADs (NaSSAs), and 5-hydroxytryptamine 
2A (5-HT2A) receptor antagonists/reuptake inhibitors (SARIs). 
All the SGAs are based on the monoamine hypothesis, with a pri-
mary mechanism consisting of monoamine reuptake inhibition 
and/or antagonism for selected monoamine receptor(s) (Stahl, 
1998). Finally, there is a class of third-generation drugs (TGAs), 
novel compounds that are in most cases characterized by non-
monoaminergic mechanisms (although some of these have been 
in development for quite a while). Most of these compounds are 
based on peptidergic, glutamatergic, or circadian rhythm-related 
mechanisms, but a few still relate to a monoaminergic mechanism 
(Racagni and Popoli, 2008). Nowadays one of the more promising 
approaches in psychiatric research is pharmacogenetics. The aim 
IntroductIon
Depressive disorders constitute a major public health issue and have 
been estimated to be the fourth major cause of disability worldwide, 
and may become second only to cardiovascular diseases in the next 
two decades (Mathers et al., 2000), thus contributing heavily to the 
global burden of diseases in man, according to Murray and Lopez 
(1997), who conducted a study for the World Health Organization 
(WHO). Unfortunately, depressed patients are not totally satisfied 
with the current effectiveness and tolerance of available antidepres-
sant (AD) medications. Less than 50% of all patients treated with 
the currently available ADs show full remission and despite the 
clear need for better therapies, recent efforts to develop novel ADs 
have been relatively unsuccessful (Agid et al., 2007). The recent 
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) 
trial showed that even with systematic measurement-based treat-
ment, approximately one-third of patients reach full remission 
after one treatment trial, with only two-thirds reaching remission 
after four treatment trials. Treatment-resistant depression (TRD) is 
therefore a common problem in the treatment of major depressive 
disorder (MDD), with 60–70% of all patients meeting the criteria 
for TRD (Rush et al., 2006a,b; Trivedi et al., 2006a,b). It becomes 
of great interest to the scientific community and to our patients 
to report, in future clinical trials, not response rates alone but also 
remission rates, in order to assess the real clinical AD efficacy. This 
is relevant in order to improve the still incomplete knowledge of 
the pathogenetic mechanisms of depression and to better under-
stand the AD mechanisms of action, in order to develop new AD 
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at different frequencies in different populations of the world (for 
information see http://www./cypalleles.ki.se/), with a consider-
able number of variants which encodes inactive isoforms or with 
decreased or negligible activity, while other variations consist of 
gene duplications (Bertilsson et al., 2002). Those gene variants are 
often associated with different drug metabolism rate. According 
to the inherited CYP2D6 alleles, individuals are classified as poor 
(PM), intermediate (IM), extensive (EM), or ultrarapid (UM) 
metabolizers. Individuals who are PMs have a combination of 
two partially or totally defective alleles and often, they complain 
of side effects and drug intolerance at low dosages of drugs for its 
accumulation. Occasionally, these individuals are labeled as non-
compliant for treatment. IMs have in their allelic combination 
one wild type allele plus one a partially or totally defective allele. 
The expected phenotype is between the EM and the PM pheno-
types. In the case of CYP2D6, there is good evidence for a linear 
relationship between gene copy number and metabolism of a 
drug (i.e., amitriptyline and nortriptyline; Grasmader et al., 2004; 
Steimer et al., 2004). It is reasonable to expect that those drugs 
predominately metabolized through CYP2D6 may also show an 
IM status due to the low hepatic content of CYP2D6 and limit-
ing enzymatic capacity. Drugs with additional metabolic routes 
(i.e., CYP2C19 and CYP3A) may have IM or EM status due to the 
additional metabolic routes for drug elimination. Individuals who 
are EM, also called normal or “wild type” have two active alleles. 
This genotype serves as the reference genotype for other stud-
ies. The UM category exists for CYP2D6 and CYP1A2 enzymes. 
UM individuals usually have multiple copies of the allele on one 
or the other chromosome, this condition increased enzymatic 
activity due to an increased the amount of protein produced 
(Gaikovitch et al., 2003). Interesting and noteworthy the preva-
lence of different genotypes and phenotypes is notably different 
depending on ethnicity.
Pharmacogenetic studies which investigated the influence of 
CYP2D6 variants on AD outcome actually do not reach univo-
cal results; this may at least partly be due to the heterogeneity of 
studied populations. Indeed, while some authors reported positive 
association with therapeutic effects (Rau et al., 2004; Tsai et al., 
2010) or side effects (Rau et al., 2004; Shams et al., 2006; Suzuki 
et al., 2006), other authors found lack of association (Murphy Jr. 
et al., 2003; Grasmader et al., 2004; Serretti et al., 2009; Murata et al., 
2010), both for therapeutic and side effects (Peters et al., 2008). 
Moreover, several authors found an association between CYP2D6 
variants and AD serum levels (Charlier et al., 2003; Grasmader et al., 
2004; Suzuki et al., 2010; Tsai et al., 2010), but without univocal 
results (Murphy Jr. et al., 2003; Ohara et al., 2003). In the case of 
CYP1A2, duplications do not occur, but polymorphisms affect-
ing transcription and translation of the encoded protein in the 
presence of inducers, such as tobacco smoke, can produce a UM 
phenotype (Sachse et al., 1999; Pavanello et al., 2005). UMs often 
requires doses of a CYP2D6-metabolized drug above (e.g., fluoxet-
ine) or below (e.g., codeine, which is a prodrug for morphine) than 
conventional dosing guidelines to achieve a therapeutic desired 
effect. The CYP2C19 gene is on another cytochrome gene active 
in the metabolism of several ADs (Liu et al., 2002b; Yin et al., 2006; 
Rudberg et al., 2008; Schenk et al., 2010), and largely investigated 
concerning AD response. Also in this case the different isoforms 
of pharmacogenetics is to detect genetic factors that determine 
variations both in clinical response and in side effects under phar-
macotherapy. It is well known that the large interpatient variability 
in clinical response to ADs is influenced by a variety of genetic as 
well as pathophysiological and environmental factors. The basis for 
such marked interindividual variations in the clinical response to 
AD treatments is not clear yet. However it seems that at least some 
of this variation has a genetic basis (Serretti et al., 2005a). Increasing 
evidence suggests that single nucleotide polymorphisms (SNPs) can 
be used in clinical association studies to determine the contribution 
of genetic variance in drugs response (Malhotra et al., 2004; Serretti 
et al., 2005a; Drago et al., 2009). In recent years, the development 
of pharmacogenetics has provided more opportunities for indi-
vidualized pharmacotherapy of depressive disorders (Perlis, 2007; 
Horstmann and Binder, 2009). At present time, most pharmacoge-
netic studies investigated genes related to metabolism, genes coding 
for receptors and transporters and genes related to the second mes-
senger system (Perlis, 2007). In this review, we summarize the major 
findings related to the pharmacogenetics of genes affecting response 
to ADs. To reach this target we reviewed the literature searching 
the MEDLINE and EMBASE (September 2010) using the search 
terms pharmacokinetics, pharmacodynamics, gene, variation, AD, 
efficacy, depression, mood disorder, genetic, candidate, cytochrome, 
P-glycoprotein (Pgp), tryptophan hydroxylase (TPH), catechol-
O-methyltransferase (COMT), monoamine oxidase A (MAO-A), 
HTT, norepinephrine transporter (NET), dopamine transporter 
(DAT), 5-HT1A, 5-HT2A, 5-HT3A, 5-HT3B, 5-HT6, angiotensin 
converting enzyme (ACE), circadian locomotor output cycles kaput 
protein (CLOCK), nitric oxide synthase (NOS), interleukin 1-beta 
(IL-1B), brain-derived neurotrophic factor (BDNF), glycogen syn-
thase kinase 3 beta (GSK-3β), adrenoreceptor beta-1 (ADRB1), 
adrenoreceptor alpha-2 (ADRA2A), dopamine receptors, Gbeta3, 
corticotropin releasing hormone (CRH) receptor (CRHR1), glu-
cocorticoid receptor (GR), glutamate receptor (also using extensive 
gene names; for overview see Table 1).
PharmacokInetIcs
cytochrome P450
Differences in AD plasma concentrations, and possibly safety, may 
be caused by polymorphisms in the genes that encode some of 
the cytochrome P450 (CYP) isoenzymes that metabolize ADs. The 
CYP superfamily is a class of proteins containing a heme cofactor 
that localize mainly to the liver. They represent the major enzymes 
responsible for the phase I oxidative reactions of many drugs and 
endogenous substances and over 50 isoenzymes are known so far 
(Ingelman-Sundberg et al., 2007). The most relevant cytochromes 
in humans are: CYP1A, CYP2A6, CYP2B6, CYP2C8, CYP2C9, 
CYP2C19, CYP2D6, CYP2E1, and CYP3A.
The metabolic activity of CYPs is genetically determined and 
mutations or polymorphisms in genes coding for CYP isoforms 
can result in enzyme variants with higher, lower or no activity. As 
shown in Table 2, the isoenzymes CYP1A2, CYP2C9/19, CYP2D6, 
and CYP3A4 are the major enzymes that catalyze AD metabolic 
reactions (Spina et al., 2008).
With regards to CYP2D6 gene in particular, its polymorphisms 
were associated with the metabolism of most AD drugs (Lin and 
Lu, 1998). So far, more than 100 different alleles were reported 
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Table 1 | Overview of genetic association studies.
Gene Principal 
polymorphism 
investigated
Alleles Amino 
acid 
change
Frequency* Region Antidepressants 
involved
Reference**
Major 
allele
Minor 
allele
P-glycoprotein rs1045642 A/C/
G/T
1145 I/? A (56%) G (44%) Coding 
exon
Paroxetine; 
citalopram; 
nortriptyline
Roberts et al. (2002), 
Gex-Fabry et al. (2008), 
Kato et al. (2008a), 
Mihaljevic Peles et al. 
(2008), Nikisch et al. 
(2008), Peters et al. 
(2008)
rs1128503 A/C/
G/T
412 G/? G (56%) A (44%) Coding 
exon
rs2032582 A/G/T 893 S/? C (54%) A (46%) Coding 
exon
rs10280101 A/C None A (85%) C (15%) Intron
rs7787082 A/G None G (82%) A (18%) Intron
rs2032583 A/G None A (85%) G (15%) Intron 
(boundary)
rs2235040 C/T None C (85%) T (15%) Intron 
(boundary)
TPH1 rs1800532 G/T None G (56%) T (44%) Intron Fluvoxamine; 
paroxetine; 
citalopram; 
typical 
neuroleptics
Serretti et al. (2001b,c), 
Anttila et al. (2007), Ham 
et al. (2007), Viikki et al. 
(2010)
TPH2 rs1843809 G/T None T (89%) G (11%) Intron Fluoxetine; 
citalopram
Peters et al. (2004), 
Tzvetkov et al. (2008), Tsai 
et al. (2009b)
rs1386494 C/T None C (87%) T (13%) Intron
rs1487276 C/T None C (87%) T (13%) Intron
rs10897346 C/T No data No freq. 
data
No freq. 
data
No data
rs1487278 C/T None T (78%) C (22%) Intron
rs2171363 A/G None G (64%) A (36%) Intron
COMT rs4680 A/G 158 
V/M
G (51%) A (49%) Coding 
exon
Fluoxetine; 
paroxetine; 
citalopram
Benedetti et al. (2009), 
Tsai et al. (2009a), 
Kocabas et al. (2010)
MAO-A uVNTR No 
data
No data No freq. 
data
No freq. 
data
Promoter Mirtazapine; 
fluoxetine
Peters et al. (2004), Tadic 
et al. (2007), Tzeng et al. 
(2009)
rs6323 G/T 297 R/R T (73%) G (27%) Coding 
exon
rs1465108 A/G None G (70%) A (30%) Intron
rs1799835 G/T 314 F/V Coding 
exon
(Continued)
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5-HTTLPR 44 bp Del/Ins long/
short
No data l (51%) s (49%) Promoter Fluvoxamine; 
paroxetine; 
citalopram; 
fluoxetine; 
nortriptyline; 
mirtazapine; 
sertraline
Zanardi et al. (2001), 
Rausch et al. (2002), Arias 
et al. (2003), Joyce et al. 
(2003), Durham et al. 
(2004), Murphy Jr. et al. 
(2004), Peters et al. 
(2004), Serretti et al. 
(2004c), Kraft et al. (2005), 
Kim et al. (2006), Smeraldi 
et al. (2006), Bozina et al. 
(2008), Huezo-Diaz et al. 
(2009), Mandelli et al. 
(2009), Min et al. (2009), 
Mrazek et al. (2009), 
Wilkie et al. (2009), Illi 
et al. (2010)
Stin2 VNTR No data No freq. 
data
No freq. 
data
Intron
rs25531 A/G None No freq. 
data
No freq. 
data
Promoter
NET rs5566 C/G 369 A/P G (100%) C (0%) Coding 
exon
Desipramine; 
paroxetine; 
sertraline; 
fluvoxamine; 
pindolol; 
nortriptyline; 
milnacipran; 
fluoxetine; 
venlafaxine
Yoshida et al. (2004), 
Hahn et al. (2005), Kim 
et al. (2006), Dong et al. 
(2009), Min et al. (2009), 
Uher et al. (2009)
rs5563 A/C 292 N/T A (100%) C (0%) Coding 
exon
rs5558 G/T 528 F/C T (100%) G (0%) Coding 
exon
rs5569 A/G 429 T/T G (57%) A (43%) Coding 
exon
rs2242446 C/T None T (73%) C (27%) 5′ UTR
rs1532701 A/G None A (53%) G (47%) Intron
rs5564 A/G None A (95%) G (5%) Intron 
(boundary)
rs1362621 A/G None A (76%) G (24%) Promoter
DAT 40-bp in exon 
15 
VNTR No data No freq. 
data
No freq. 
data
3′ UTR Mirtazapine; 
venlafaxine; 
citalopram
Kirchheiner et al. (2006), 
Lavretsky et al. (2008)
5-HT1A 
receptor
rs6295 C/G None C (56%) G (44%) Promoter Fluoxetine; 
nefazodone; 
fluvoxamine; 
citalopram
Perez et al. (1997), 
Lemonde et al. (2004), 
Serretti et al. (2004a), 
Arias et al. (2005), Hong 
et al. (2006), Parsey et al. 
(2006), Yu et al. (2006), 
Kato et al. (2009), 
Villafuerte et al. (2009)
Table 1 | Continued
(Continued)
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Table 1 | Continued
Gene Principal 
polymorphism 
investigated
Alleles Amino 
acid 
change
Frequency* Region Antidepressants 
involved
Reference**
Major 
allele
Minor 
allele
rs1800042 A/G 273 
G/D
No freq. 
data
No freq. 
data
Coding 
exon
rs1799921 A/G 28 I/V A (99%) G (1%) Coding 
exon
rs1800044 G/T 220 R/L No freq. 
data
No freq. 
data
Coding 
exon
rs1799920 A/G 22 G/S No freq. 
data
No freq. 
data
Coding 
exon
rs10042486 C/T None C (50%) T (50%) Promoter
rs1364043 G/T None T (78%) G (22%) Downstream
5-HT2A 
receptor
rs6311 C/T None C (53%) T 47%) Promoter Citalopram; 
paroxetine; 
fluvoxamine
Choi et al. (2005), Kato 
et al. (2006)
rs6313 A/G 34 S/S G (53%) A (47%) Coding exon
rs6314 A/G 452 H/Y G (94%) A (6%) Coding exon
5-HT3A 
receptor
rs1062613 C/T None C (78%) T (22%) 5′ UTR Paroxetine; 
fluvoxamine
Tremblay et al. (2003), 
Kato et al. (2006), Sugai 
et al. (2006), Tanaka et al. 
(2008)
C195T C/T No data No freq. 
data
No freq. 
data
No data
5-HT3B 
receptor
(-100 -102) 
AAG del/ins
long/
short
No data No freq. 
data
No freq. 
data
No data
rs1176744 A/C 129 Y/S A (71%) C (29%) Coding exon
rs35312182 A/G None A (96%) G (4%) Intron
5-HT6 receptor rs1805054 C/T 89 Y/Y C (88%) T (12%) Coding exon Venlafaxine; 
fluoxetine
Wu et al. (2001), Lee 
et al. (2005)
ADRA2A rs11195419 A/C None C (88%) A (12%) 3′ UTR Nortriptyline Perroud et al. (2009)
ADRB1 G1165C C/G No data No freq. 
data
No freq. 
data
No data Various 
antidepressant; 
citalopram
Zill et al. (2003), Crowley 
et al. (2008)
D2 receptor rs1801028 C/G 311 S/C C (98%) G (2%) Coding exon Various 
antidepressant; 
lamotrigine; 
olanzapine; 
fluoxetine
Serretti et al. (2001a, 
2004b), Benedetti et al. 
(2003b), Garriock et al. 
(2006), Perlis et al. (2010)
rs4245147 C/T None C (51%) T (49%) Intron
D3 receptor rs167770 A/G None A (71%) G (29%) Intron
rs6280 C/T 9 G/S T (65%) C (35%) Coding exon
rs2134655 C/T None C (72%) T (28%) Intron
D4 receptor rs936461 A/G None G (65%) A (35%) Promoter
VNTR in exon 
3 
VNTR No data No freq. 
data
No freq. 
data
Coding exon
(Continued)
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GNB3 rs5443 C/T 275 S/S C (62%) T (38%) Coding exon Fluoxetine; 
nortriptyline; 
paroxetine; 
escitalopram; 
mirtazapine
Zill et al. (2000), Joyce 
et al. (2003), Serretti et al. 
(2003b), Lee et al. (2004), 
Hong et al. (2006), Kang 
et al. (2007), Wilkie et al. 
(2007), Kato et al. 
(2008b), Lin et al. (2009), 
Keers et al. (2010a)
CRHR1 rs242941 G/T None G (69%) T (31%) Intron Fluoxetine Licinio et al. (2004), Liu 
et al. (2007)
rs1876828 A/G None G (78%) A (22%) Intron
rs242939 A/G None A (93%) G (7%) Intron
CRHR2 rs2270007 C/G None C (83%) G (16%) Intron Citalopram Papiol et al. (2007)
GR ER22/23EK No 
data
No data No freq. 
data
No freq. 
data
No data Various 
antidepressant
van Rossum et al. (2006), 
Uher et al. (2009)
BclI No 
data
No data No freq. 
data
No freq. 
data
No data
rs852977 A/G None A (66%) G (34%) Intron
rs10482633 G/T None T (80%) G (20%) Intron
rs10052957 A/G None G (65%) A (35%) Promoter
BDNF rs6265 C/T 66 V/M C (80%) T (20%) Coding exon Various 
antidepressant; 
citalopram; 
fluoxetine
Choi et al. (2006), 
Gratacos et al. (2008), 
Licinio et al. (2009), 
Domschke et al. (2010), 
Zou et al. (2010a)
rs61888800 G/T None G (70%) T (30%) 5′ UTR
rs7124442 C/T None T (66%) C (34%) 3′ UTR
rs11030104 A/G None A (77%) G (23%) Intron
NTRK2 rs2289657 A/C 600 I/I C (95%) A (5%) Coding exon Various 
antidepressant
Dong et al. (2009)
rs56142442 C/T 794 P/P No freq. 
data
No freq. 
data
Coding exon
rs2289658 C/T None T (96%) C (4%) Intron 
(boundary)
rs2289657 A/C 600 I/I C (95%) A (5%) Coding exon
rs2289656 A/G None G (82%) A (18%) Intron 
(boundary)
Table 1 | Continued
**The table indicates the main references.
*The allele frequencies are referred to Caucasians.
of the gene allowed a classification in phenotypes, with a group of 
subjects labeled as EM, another one with impaired catalytic capac-
ity, called PM (Smith et al., 1998a,b); and an UM group (Rudberg 
et al., 2008). In conclusion, the pharmacokinetics of ADs is signifi-
cantly altered, in particular by CYP2D6 and more marginally by 
CYP2C19 polymorphisms. However, it is still controversial whether 
therapeutic efficacy may be improved and/or adverse effects could 
be prevented by the use of genotyping procedures, particular con-
sidering that genotype often do not correspond to a well-defined 
phenotype as state above. With regard to this, the recent approval 
by the FDA of the pharmacogenetic test, the AmpliCyp CYP450 
Test (Roche Molecular System Inc.), assessing both polymorphic 
genes CYP2D6 and CYP2C19, may be of help to validate studies 
on personalized therapy of depression.
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Table 2 | Cytochrome P450 isoforms responsible for the 
biotransformation of antidepressants. Based on Spina et al. (2008).
Antidepressant Enzymes responsible for  
 biotransformation
Tricyclic antidepressants CYP2C19, CYP1A2, CYP3A4 
(demethylation)
Tricyclic antidepressants CYP2D6 
(hydroxylation)
Fluoxetine CYP2D6, CYP2C9, CYP2C19,  
 CYP3A4
Paroxetine CYP2D6, CYP3A4
Fluvoxamine CYP1A2, CYP2D6
Sertraline CYP2C9, CYP2C19, CYP2D6,  
 CYP3A4
Citalopram CYP2C19, CYP2D6, CYP3A4
Escitalopram CYP2C19, CYP2D6, CYP3A4
Venlafaxine CYP2D6, CYP3A4
Duloxetine CYP2D6, CYP1A2
Mirtazapine CYP2D6, CYP1A2, CYP3A4
Reboxetine CYP3A4
Trazodone CYP3A4
Nefazodone CYP3A4
Bupropion CYP2B6
Agomelatine CYP1A2
P-glycoProteIn
P-glycoprotein is a member of the ATP-binding cassette superfamily 
of membrane transport proteins encoded by the ATP-binding cas-
sette, subfamily B, member 1 (ABCB1) gene [alternate name multi-
drug resistance protein 1 (MDR1)], it is responsible for the efflux of 
many drugs. It represents a major component of the blood–brain 
barrier (Schinkel et al., 1994) and the intestinal barrier (Van Asperen 
et al., 1998), and it contributes to renal and biliary elimination of 
drugs (Kusuhara et al., 1998; Chiou et al., 2000). Because of its loca-
tion at the blood–brain barrier, Pgp may regulate the concentration 
of ADs in the brain. For paroxetine, venlafaxine, and fluoxetine the 
data indicate that they might be Pgp substrates; for citalopram the 
data are conflicting (Rochat et al., 1999; Uhr et al., 2000). Several 
variants of ABCB1 are known (Kioka et al., 1989; Mickley et al., 1998; 
Hoffmeyer et al., 2000; Ito et al., 2001), among these three – C3435T 
(rs1045642), C1236 (rs1128503), and G2677T (rs2032582) – have 
been associated with altered Pgp activity. Studies investigating the 
influence of these functional polymorphisms on ADs response have 
given contradictory results (Roberts et al., 2002; Laika et al., 2006; 
Fukui et al., 2007). Indeed, while some authors found positive asso-
ciations between rs2032582 (Kato et al., 2008a; Nikisch et al., 2008) 
or rs1045642 (as well as haplotype with rs2032582 and rs1128503; 
(Kato et al., 2008a) and AD response or side effects (nortriptyline-
inducted postural hypotension; (Roberts et al., 2002), other authors 
failed to find positive association for rs2032582 and rs1045642 (Gex-
Fabry et al., 2008; Mihaljevic Peles et al., 2008), also considering 
together with rs1128503 (Peters et al., 2008). Finally negative find-
ings have been reported also for rs10280101, rs7787082, rs2032583, 
rs2235040 (Perlis et al., 2010), and rs2032582 (Laika et al., 2006).
PharmacodynamIcs
monoamIne metabolIc enzymes
Tryptophan hydroxylase
Tryptophan hydroxylase is an enzyme involved in the synthesis 
of serotonin. There are two distinct TPH genes that encode two 
different homologous enzymes TPH1 and TPH2. TPH1 is mostly 
expressed in tissues that express serotonin in the skin, gut, and 
pineal gland but it is also expressed in the central nervous system 
(CNS). TPH2 is exclusively expressed in neuronal cell types and is 
the predominant isoform in the CNS. TPH gene has been consid-
ered one of the most promising genes concerning the genetic modu-
lation of AD response. Several studies found an association between 
TPH1 polymorphisms and suicidal behavior and worse response 
to SSRIs (Serretti et al., 2001b,c; Ham et al., 2007). Unfortunately 
following studies found controversial results (Yoshida et al., 2002; 
Rujescu et al., 2003; Bellivier et al., 2004; Peters et al., 2004; Serretti 
et al., 2004c; Ham et al., 2005; Hong et al., 2006; Kato et al., 2007; 
Illi et al., 2009). Nevertheless recently studies have shown an asso-
ciation between rs1800532 and AD response, concerning both 
clinical response (Anttila et al., 2007; Viikki et al., 2010) and side 
effect profile (Secher et al., 2009), suggesting that the role of this 
polymorphisms is not yet deeply understood and needs further 
investigation, particularly considering also other polymorphisms 
in the same gene and/or in other correlated genes [like 5-HT2A, 
G protein beta 3 subunit (GNB3), and COMT; (Anttila et al., 2007; 
Secher et al., 2009]. Also TPH2 polymorphisms have been asso-
ciated with AD response: rs1843809, rs1386494, and rs1487276 
(Peters et al., 2004), rs10897346 and rs1487278 (Tzvetkov et al., 
2008), rs2171363 (Tsai et al., 2009b). Although these results need 
to be clearly replicated, overall these data suggested a role for TPH2 
gene in AD pharmacogenetics.
Catechol-O-methyltransferase
Catechol-O-methyltransferase is one of several enzymes that degrade 
catecholamines such as dopamine, epinephrine, and norepinephrine 
(NE). COMT is an intracellular enzyme located in the postsynaptic 
neuron. The COMT gene have several allelic variants, among these 
the most well-studied is rs4680, results in a change in the enzyme 
structure [Val(108/158)Met], which influences activity (high activ-
ity in Val/Val, intermediate activity in Val/Met, and low activity in 
Met/Met genotype; (Lachman et al., 1996). This polymorphism was 
associated with AD treatment, in particular rs4680 seems to influ-
ence fluoxetine and paroxetine response (Benedetti et al., 2009; Tsai 
et al., 2009a). However, other studies showed contrasting results 
with other drugs (Szegedi et al., 2005; Arias et al., 2006; Baune et al., 
2008a; Yoshida et al., 2008; Benedetti et al., 2009). Particularly Met/
Met genotype has been associated both with better (Baune et al., 
2008a; Yoshida et al., 2008; Benedetti et al., 2009; Tsai et al., 2009a) 
and worse response (Szegedi et al., 2005; Arias et al., 2006). On the 
other hand, Hilli et al. (2009) did not find any association between 
this variant and AD response. Moreover stressful life events do not 
seem to interact with rs4680 to predict treatment outcome (Bukh 
et al., 2010). Recently Perlis et al. (2009a) and Kocabas et al. (2010) 
investigated other SNPs within the COMT founding more or less 
association with citalopram or other AD response. Although so far 
no replication studies have been performed, this result supports the 
role of COMT gene variants on the AD response.
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Serretti et al. (2007b) showed a significant association between the 
s/s variant of 5-HTTLPR and remission rate and between both 
s/s and s/l variants and response rate. Nonetheless, a more recent 
meta-analysis performed by Taylor et al. (2010) failed to repli-
cate this result, probably because they did not consider separately 
Caucasian and Asian samples. Other studies focused on the possible 
interaction between genetic and environment finding that stressful 
life events could interact with 5-HTTLPR genotype to determi-
nate AD response (Bukh et al., 2009; Mandelli et al., 2009; Keers 
et al., 2010b), although this topic is still controversial (Coventry 
et al., 2010). These findings were found to be more consistent in 
Caucasian than in Asian samples, probably for a different preva-
lence of this mutation in diverse ethnicities. Interestingly Murphy Jr. 
et al. (2004) showed an interaction between the HTTLPR genotype 
and the AD used on the side effect profile suggesting that the effect 
of this polymorphism on outcome may depend on the mecha-
nism of AD action as well. Another polymorphism influencing 
SERT expression, described as a 17-bp VNTR polymorphism, was 
identified by Ogilvie et al. (1996) within intron 2 (STin2). Some 
evidences suggested this polymorphism as a risk factor for depres-
sive disorder (Ogilvie et al., 1996; Gutierrez et al., 1998; MacKenzie 
and Quinn, 1999) and suicide behavior (Gaysina et al., 2006; Lopez 
de Lara et al., 2006), creating a synergistic effect with 5-HTTLPR 
(Hranilovic et al., 2004). Moreover, different authors reported an 
effect of STin2 on AD response (Kim et al., 2000, 2006; Peters et al., 
2004; Bozina et al., 2008; Min et al., 2009; Mrazek et al., 2009; Wilkie 
et al., 2009), even though not consistently (Ito et al., 2002; Dogan 
et al., 2008; Huezo-Diaz et al., 2009). More recently rs25531, a 
SNP located just upstream of the 5-HTTLPR, was found to impact 
the response to AD pharmacotreatment and, consistently, it was 
shown to modulate the effect of the other 5-HTTLPR alleles (Kraft 
et al., 2005; Smeraldi et al., 2006). Nevertheless the results are still 
controversial with both negative (Kraft et al., 2007; Maron et al., 
2009; Baffa et al., 2010) and positive findings (Kraft et al., 2005; 
Mrazek et al., 2009; Bonvicini et al., 2010).
Norepinephrine transporter (SLC6A2)
The norepinephrine transporter or NET [or noradrenaline trans-
porter (NAT)] is encoded by the SLC6A2 gene. It is a monoamine 
transporter that transports the neurotransmitters NE (noradrena-
line) from the synapse back to cytosol, hence other transporters 
vesicular monoamine transporter (VMAT) sequester NE into 
vesicles for later storage and release. Several investigators have 
studied the relationship between NET genetic polymorphisms 
and susceptibility to psychiatric disorders, including MD, bipolar 
disorder, schizophrenia, and alcohol dependence (Owen et al., 
1999; Leszczynska-Rodziewicz et al., 2002; Samochowiec et al., 
2002; Zill et al., 2002), without observing major findings. Several 
genetic variants are known in the human NET gene: rs5566 
(A369P), rs5563 (N292T), rs5558 (F528C), rs5569 (G1287A), and 
rs2242446 (T-182C) variants were proved to be functional and 
impact the AD effect (Yoshida et al., 2004; Hahn et al., 2005; Kim 
et al., 2006). With particular regard to AD response, rs5569, a silent 
mutation is associated with the cerebrospinal fluid concentration 
of 3-methoxy-4-hydroxyphenylglycol, a major NE metabolite 
(Jonsson et al., 1998), and with the response to  methylphenidate, 
Monoamine oxidase A
Monoamine oxidases are a family of enzymes that catalyze the 
oxidation of monoamines. In humans there are two types of MAO: 
MAO-A and MAO-B, and both are found in CNS, in particular in 
neurons and astroglia. The MAO-A, coded by the MAO-A gene, 
metabolizes several important amines and catecholamines includ-
ing dopamine, serotonin, and NE. Polymorphism in the gene’s 
promoter region is due to a repetitive sequence [variable number 
tandem repeat (VNTR)] located 1.2 kb upstream of the MAO-A 
gene, regulates the activity of the MAO-A gene and have been linked 
to variations in the biological activity and also influences the con-
centration of serotonin (Sabol et al., 1998). Because the activity 
of MAO-A influences neurotransmitter concentrations, polymor-
phisms in these genes may affect AD response. Researchers like 
Tadic et al. (2007) and more recently Tzeng et al. (2009) reported 
that the VNTR polymorphism in the MAO-A gene promoter region 
was associated with mirtazapine response. Nevertheless, as a matter 
of fact, several reports did not found any correlation between this 
polymorphism and the AD response (Cusin et al., 2002; Muller 
et al., 2002; Yoshida et al., 2002; Peters et al., 2004). Other poly-
morphisms within this gene were more marginally studied, with 
some positive but not replicated results. Particularly Peters et al. 
(2004) reported an association between rs1465108 and rs6323 and 
fluoxetine response whilst Tadic et al. (2007) found an association 
between rs1799835 and mirtazapine response only in the female 
sample). Finally an effect of the rs6323 genotype on the placebo 
response has been reported (Leuchter et al., 2009).
monoamIne transPorters
Serotonin transporter (SLC6A4)
The serotonin transporter (SERT or SLC6A4) regulates brain 
serotonin neurotransmission by transporting the neurotransmit-
ter serotonin from synaptic space to presynaptic neurons. It is the 
principal site of action of many ADs (mainly SSRI, SNRI, TCA) 
and it represents a target of primary interest in the AD pharma-
cogenetics. The most investigated variant of this gene is located 
in the promoter region (5-HTTLPR) and it is able to impact the 
expression of the SERT. This polymorphism was firstly described 
in 1996 by Heils et al. (1996) as an insertion/deletion of 44 bp 
involving 2 U in a sequence of 16 repeated elements: the long (l) 
allele has twice the expression in the basal state than the short (s) 
form. 5-HTTLPR polymorphism has been studied in association 
with affective symptomatology (anxiety disorders, substance abuse, 
bipolar disorder, eating disorders, and depression) and with patho-
logical behaviors and personality traits related to anxiety, impul-
sivity, and stress (Serretti et al., 2006). Moreover, several reports 
found an association with AD response, in particular, studies in 
Caucasians showed a positive association between L allele and bet-
ter response (Smeraldi et al., 1998; Pollock et al., 2000; Zanardi 
et al., 2000, 2001; Rausch et al., 2002; Arias et al., 2003; Joyce et al., 
2003; Durham et al., 2004; Murphy Jr. et al., 2004; Serretti et al., 
2004c; Bozina et al., 2008; Huezo-Diaz et al., 2009; Mandelli et al., 
2009; Mrazek et al., 2009; Illi et al., 2010) although negative find-
ings have been reported as well (Hu et al., 2007; Kraft et al., 2007; 
Dogan et al., 2008; Maron et al., 2009; Wilkie et al., 2009; Baffa 
et al., 2010; Reimherr et al., 2010). A meta-analysis performed by 
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(Lesch and Gutknecht, 2004; Sharp et al., 2007). The 5-HT1A 
receptor also serves as the predominant (somatodendritic) autore-
ceptor of the raphe nuclei, reducing the firing rate of these neurons, 
the amount of serotonin released per action potential, and the 
synthesis of the neurotransmitter; and thus by implication, the 
serotonergic activity of its projection areas (Wang and Aghajanian, 
1977; Verge et al., 1985; Sprouse and Aghajanian, 1986; Blier and 
de Montigny, 1987; Hutson et al., 1989; Meller et al., 1990; Hjorth 
and Sharp, 1991; Kreiss and Lucki, 1994). The 5-HT1A receptor is 
coded by the 5-hydroxytryptamine receptor 1A (HTR1A) gene. A 
role for this gene in the AD response has been postulated because 
several AD desensitize raphe 5-HT1A autoreceptors, leading to an 
enhancement of the serotonergic neurotransmission that could 
be associated with the AD effect of these drugs. Moreover there 
are some evidences that the block of the 5-HT1A autoreceptors 
may accelerate the AD action (Perez et al., 1997). The most inves-
tigated HTR1A variants are: C(−1019)G (rs6295); Gly272Asp 
(rs1800042); Ile28Val (rs1799921); Arg219Leu (rs1800044); and 
Gly22Ser (rs1799920). Among these, the most investigated one 
concerning AD response is rs6295, which is located in the pro-
moter region of the gene. The rs6295 G allele has been associated 
with an up regulation of the expression of the receptor (Lemonde 
et al., 2003; Albert and Lemonde, 2004), moreover there are some 
evidences suggesting that G allele carriers have higher risks for 
depression and suicidal behavior and of being more resistant to AD 
treatment (Lemonde et al., 2003, 2004; Serretti et al., 2004a; Arias 
et al., 2005; Hong et al., 2006; Parsey et al., 2006; Yu et al., 2006; 
Kato et al., 2009; Villafuerte et al., 2009). In particular, Lemonde 
et al. (2004) reported that AD response to the SSRI fluoxetine, 
NARI nefazodone, and 5-HT1A agonist flibanserin, was associ-
ated with this polymorphism. Nonetheless other authors reported 
conflicting results (Peters et al., 2004; Serretti et al., 2004a; Mandelli 
et al., 2007; Noro et al., 2010). Noteworthy, Yu et al. (2006) found 
an association between rs6295 and AD response only in females, 
showing an interaction with gender, and Baune et al. (2008b) 
showed an association only in patients with melancholic depres-
sion. No interaction has been found between rs6295 and stressful 
life events with the AD response (Bukh et al., 2010). Another SNP 
associated with better AD response was rs1800042, although nega-
tive results are reported as well (Suzuki et al., 2004; Yu et al., 2006; 
Levin et al., 2007). With regard to drug related adverse events, 
neither rs1800042 nor rs6295 seem to be significantly associated 
to paroxetine discontinuation syndrome (Murata et al., 2010). Also 
other 5-HT1A polymorphisms were studied in association with 
AD response. A recent paper reported that rs10042486 C/C and 
rs1364043 T/T genotypes were strongly associated with a better 
response to AD drugs (Kato et al., 2009). All these data suggested 
that other 5-HT1A gene variants need to be considered in order 
to better elucidate the role of this gene on AD response (Drago 
et al., 2008).
5-HT2A receptor
5-Hydroxytryptamine 1A receptor is a G protein-coupled receptor 
coded by the HTR2A gene; it is expressed widely throughout the 
CNS, near most of the serotonergic terminal rich areas, includ-
ing neocortex (mainly prefrontal, parietal, and somatosensory 
a drug with  noradrenergic action, in attention deficit hyperactiv-
ity disorder (ADHD; (Yang et al., 2004). The association between 
this polymorphism and the AD response was previously examined 
in Japanese patients by Yoshida et al. (2004): they reported that 
the NET G1287A polymorphism (A/A genotype) was associated 
with the onset of response but not the final clinical improve-
ment. Moreover, Kim et al. (2006) showed a positive association 
between G/G rs5569 genotype and better response to nortriptyl-
ine, although no effect on SSRIs response has been detected. The 
NET T-182C polymorphism was first reported by Zill et al. (2002) 
and the presence of the T allele was associated with a superior 
response to milnacipran (Yoshida et al., 2004; for a review see 
Higuchi, 2010). Consistently one other study did not find any 
association between these polymorphisms and SSRIs (fluoxetine, 
paroxetine, or citalopram) or venlafaxine response in an Asiatic 
sample of depressed patients (Min et al., 2009). Recently other 
NET polymorphisms have been investigated: Uher et al. (2009) 
showed an association between rs60329 and rs1532701 polymor-
phism and favorable response to treatment with nortriptyline, 
and Dong et al. (2009) found that the rs5564 and rs1362621 were 
associated with remission with desipramine and fluoxetine treat-
ment. Nevertheless, Baffa et al., 2010) did not found any asso-
ciation with seven polymorphisms in the promoter, intronic and 
exonic region of NET (rs35915, rs28386840, rs168924, rs2242446, 
rs36017, rs47958, rs171798). However, results are not unequivocal, 
and replication studies are warranted.
Dopamine transporter
The DAT (SLC6A3) acts to terminate dopaminergic neurotransmis-
sion through reuptake of dopamine from the synaptic cleft into 
presynaptic neurons. DAT is thought to be implicated in several 
dopamine-related disorders, including ADHD (Barr et al., 2000), 
schizophrenia (Prata et al., 2009), and alcoholism (Heinz et al., 
2004). SLC6A3 gene has a VNTR at the 3′ end (rs28363170; Sano 
et al., 1993). This polymorphism has been studied in association 
with several diseases, including bipolar affective disorders (Waldman 
et al., 1997; Greenwood et al., 2001). AD drugs, in particular SSRIs, 
modulate availability of DAT, and dopaminergic mechanisms may 
play an important role in AD drug action (Ichikawa and Meltzer, 
1995; Smith et al., 2000; Kugaya et al., 2003; Willner et al., 2005; 
Zhou et al., 2005). However, according to our best knowledge, the 
relationship between the DAT polymorphism and AD response has 
been weakly studied. Kirchheiner et al. (2006) showed an associa-
tion between the 9/10 and 9/9 genotypes and a higher risk of poorer 
and slower response to various AD drugs than the 10/10 genotype. 
Moreover, the 10/10 genotype seems to be associated with an endo-
phenotype (Gottesman and Gould, 2003) of late-life depression 
that responds preferentially to methylphenidate added to a SSRI 
(Lavretsky et al., 2008).
monoamIne recePtors
5-Hydroxytryptamine 1A or serotonin-1A receptors
Serotonin-1A receptors is a Gprotein-coupled receptor located 
both pre- and post-synaptically and widely distributed in regions 
that receive serotonergic input from the raphe nuclei: the fron-
tal cortex, septum, amygdala, hippocampus, and hypothalamus 
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SSRIs treatment showed no association with HTR3B rs1176744 
(Suzuki et al., 2006; Tanaka et al., 2008), HTR3A rs1062613 and 
C195T (Sugai et al., 2006), as well as no association has been 
found between HTR3A (rs1062613) and HTR3B (rs35312182 
and rs1176744) polymorphisms and paroxetine discontinuation 
syndrome (Murata et al., 2010).
5-HT6 receptor
The 5-HT6 receptor is a G protein-coupled receptor which is 
expressed almost exclusively in the brain. Genetic variants within 
this gene likely have an effect on brain and several studies have 
investigated whether 5-HT6 polymorphisms are associated with 
brain-related variables, such as neuropsychiatric disorders. In this 
regard, several studies showed an implication of this gene in some 
behavior trait (Ballaz et al., 2007; Mitchell et al., 2007). Moreover, it 
seems to be involved in AD mechanism (Svenningsson et al., 2007; 
Wesolowska and Nikiforuk, 2007). The C267T variant (rs1805054), 
in the first exon, may has a role in the modulation of AD response 
as well (Kohen et al., 1996; Lee et al., 2005). Indeed, this polymor-
phism (rs1805054) has been investigated for association with AD 
response in several studies. Despite preliminary negative results 
(Wu et al., 2001), a subsequent study reported that C/T carriers 
showed better AD response (Lee et al., 2005). Nevertheless, this 
finding has not been replicated by further studies (Illi et al., 2009; 
Wilkie et al., 2009).
Adrenoreceptor beta-1 and adrenoreceptor alpha-2
The ADRB1 and ADRA2A are G protein associated receptor: 
ADRB1 stimulates adenylate cyclase while alpha 2 adrenorecep-
tor inactivates adenylate cyclase. A recently identified functional 
polymorphism in the ADRB1 G(1165)C leading to the amino acid 
variation Gly389Arg may play a functional role, and it was associ-
ated with an enhanced coupling to the stimulatory Gs protein and 
increased adenylate cyclase activation, resulting in a better and 
faster response to AD treatment (Zill et al., 2003). Nevertheless, 
Crowley et al. (2008) failed to confirm the relevance of this gene 
in modulating the response to citalopram treatment. ADRA2A 
gene, it seems to be relate to the pretreatment hypothalamic–
pituitary– adrenal (HPA) axis hyperactivity and increased adren-
ocorticotropin in male depressed patients (Haefner et al., 2008). 
Recently, Perroud et al. (2009) showed an association between 
rs11195419 ADRA2A polymorphism and suicidality ideation 
among nortriptyline treated patients.
Dopamine receptors
Dopamine receptors are divided into D1-like family (D1 and D5, 
which are coupled to a Gs protein and activate adenylate cyclase), 
and D2-like family (D2, D3, and D4, which are coupled to a Gi 
protein and inhibit adenylate cyclase). Only the D2-like family 
was associated to depressive disorder. Focusing on AD response, 
we have some line of evidence suggesting a role for D2 recep-
tor as well (Maj et al., 1989; Dziedzicka-Wasylewska and Solich, 
2004; Willner et al., 2005). A functional polymorphism (S311C, 
rs1801028) within D2 receptor gene has been repeatedly inves-
tigated without finding any influence on AD response (Serretti 
et al., 2001a, 2004b; Benedetti et al., 2003b). However, a recent 
study showed an association between D2 rs4245147 SNP and 
cortex) and the olfactory tubercle. An increasing number of 
studies suggested that HTR2A levels and activity are altered in 
psychiatric disorders like MDD (Yatham et al., 1999; Meyer et al., 
2001; Yamauchi et al., 2005; Bhagwagar et al., 2006), evidence sup-
ported also by animal studies (Skrebuhhova et al., 1999). The most 
widely investigated polymorphisms of HTR2A gene are: A-1438G 
(rs6311), C102T (rs6313), and His452Tyr (rs6314). HTR2A vari-
ations have been investigated as functional candidates in several 
psychiatric disorders such as schizophrenia, ADHD, affective dis-
orders, eating disorders, anxiety disorders, obsessive compulsive 
disorders, suicide, Alzheimer’s disease. In particular, several stud-
ies have been shown an association between rs6311 polymorphism 
and mood disorders, bipolar disorder, and MDD (Chee et al., 
2001; Choi et al., 2004), such as with AD response (Choi et al., 
2005; Kato et al., 2006). A weak link has been found between the 
rs6313 SNP and schizophrenia, moreover, this polymorphism has 
been studied in relation to suicide attempts (Williams et al., 1996; 
Vaquero-Lorenzo et al., 2008). Consistently, Minov et al. (2001) 
showed an association between the 5-HT2A rs6313 SNP (102T/C) 
and AD response. These two variants (rs6311 and rs6313) are in 
linkage disequilibrium (LD) and they can be considered together 
(Spurlock et al., 1998), therefore studies by Choi et al. (2005) 
and Kato et al. (2006) may be considered replications of results 
from Minov et al. (2001). On the other side there are studies that 
failed to replicate positive results (Cusin et al., 2002; Sato et al., 
2002; Peters et al., 2004; Yoshida et al., 2004; Hong et al., 2006; 
Suzuki et al., 2006; Illi et al., 2009). Several other variants have 
been reported to influence AD response (Cusin et al., 2002; Peters 
et al., 2004, 2009; McMahon et al., 2006; Perlis et al., 2009b; Uher 
et al., 2009; Wilkie et al., 2009; Horstmann et al., 2010; Kishi et al., 
2010; Lucae et al., 2010). Overall data suggested a role for the 
5-HT2A gene in the AD response, although a wider knowledge 
of this gene is needed in order to better disentangle this issue 
(Serretti et al., 2007a).
5-HT3A, 3B receptors
The 5-HT3 receptor is expressed throughout the central and 
peripheral nervous systems and mediates a variety of physio-
logical functions; it is the only ion channel subtype in the serot-
onin family. Five different subunits, A–E, of the 5-HT3 receptor 
have been identified. Association studies have been carried out 
to establish causal relationships between genetic variants within 
genes encoding 5-HT3A and 5-HT3B and side effects profile 
rather than clinical response. Yamada et al. (2006) showed an 
association between haplotype block in the 5-HT3B gene [that 
includes Y129S (rs1176744) polymorphism] and MD in women 
and in patients with bipolar affective disorder (Frank et al., 2004). 
Likewise, a common variation in the regulatory region of the 
5-HT3A gene C178T has been associated with bipolar affective 
disorder in Caucasians (Niesler et al., 2001), although a recent 
study on Japanese patients did not confirm this result (Yamada 
et al., 2006). Consistently HTR3A rs1062613 (C178T) and two 
polymorphisms in HTR3B (−100 −102 AAG deletion variant and 
rs1176744) have been found to be associated with chemotherapy 
and paroxetine treatment induced vomiting and nausea (Tremblay 
et al., 2003; Kato et al., 2006; Sugai et al., 2006; Tanaka et al., 
2008). Nevertheless, studies on gastrointestinal side effects during 
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lamotrigine response in a sample of bipolar depressed patients 
(Perlis et al., 2010), suggesting a role of this gene in AD response 
as well. In the same study (Perlis et al., 2010) founded an asso-
ciation between three D3 receptor SNPs (rs167770, rs6280, and 
rs2134655) and olanzapine/fluoxetine combination response in 
a sample of bipolar I depressed patients. Moreover, they reported 
a marginal association between D4 receptor SNP rs936461 and 
lamotrigine response (Perlis et al., 2010). Several studies inves-
tigated VNTR polymorphism in exon 3 of D4 receptor gene, 
in relationship with AD response, unfortunately with negative 
results (Serretti et al., 1999, 2001a), except for Garriock et al. 
(2006) who found a significant modulation effect on various AD 
medications.
Intracellular sIgnal transductIon Pathways
G protein beta 3 subunit
The β3 subunit of the G protein complex, encoded by GNB3 gene, 
is present in all cells of the body and it has a key role in the down-
stream signaling cascade following monoamine receptors activa-
tion (Hamm, 1998). For this reason a possible involvement in the 
pharmacogenetic of AD response has been suggested as well. The 
C825T (rs5443) polymorphism is the most investigated variant 
within the GNB3 gene in this field. It was associated with AD treat-
ment response; particularly the T variant seems to predict bet-
ter AD response. Nonetheless also in this case both opposite and 
negative results have been reported as well (Zill et al., 2000; Joyce 
et al., 2003; Serretti et al., 2003b; Lee et al., 2004; Hong et al., 2006; 
Kang et al., 2007; Wilkie et al., 2007; Kato et al., 2008b; Lin et al., 
2009; Keers et al., 2010a). Finally, Anttila et al., 2007) failed to find 
any association between this polymorphism and ECT response in 
depressed patients.
hyPothalamIc–PItuItary–adrenal axIs and stress hormone 
system
CRH receptors (CRHR1 and CRHR2)
The principal neuro-endocrine regulator of the HPA axis is the 
CRH, which plays an important role in coordinating the endocrine, 
autonomic, immune and behavioral responses to stress. Several 
studies showed a key role of CHR in depression (Nemeroff et al., 
1984, 1988; Brady et al., 1992; Raadsheer et al., 1994; Michelson 
et al., 1997; Gold and Chrousos, 2002; Liu et al., 2002a). Consistently 
most AD treatment seems to attenuate or normalize HPA axis activ-
ity (De Bellis et al., 1993; Ising et al., 2005; Ising and Holsboer, 
2007; Schule et al., 2009). In the CNS there are two fundamental 
subtypes of CRH receptors: CRHR1 and CRHR2. CRHR1 gene is 
considered to play a key role in mediating the CRH elicited effects 
in depression and anxiety (Van Pett et al., 2000). Moreover, CRHR1 
antagonists have consistently demonstrated AD properties in exper-
imental animals and humans (Seymour et al., 2003; Overstreet and 
Griebel, 2004; Kehne, 2007) even if this finding was not constantly 
replicated (Binneman et al., 2008). Several polymorphisms, in par-
ticular the rs242941 G/G genotype and one haplotype including 
two other SNPs beyond rs242941 (rs1876828 and rs242939), were 
found to be related to fluoxetine response (Licinio et al., 2004; Liu 
et al., 2007).
Moreover, Papiol et al., 2007 found an association between 
CRHR2 gene rs2270007 and citalopram response.
Glucocorticoid receptor
Hyperactivity of HPA axis might be caused by impaired glucocor-
ticoid signaling. Glucocorticoids act through the GR (or NR3C1). 
Within this gene several polymorphisms have been associated with 
MDD and AD response. In particular, the BclI and ER22/23EK 
polymorphisms were associated with susceptibility to develop MD 
(van Rossum et al., 2006). In addition, the ER22/23EK polymor-
phism was associated with a faster clinical response to AD treatment 
(van Rossum et al., 2006). Recently, these results were not repeated 
in Korean depressive patients (Lee et al., 2009). Brouwer et al. (2006) 
found that carriers of the BcII polymorphism have higher base-
line ATCH values and they showed a trend toward lower decrease 
of Hamilton Rating Scale for Depression rates than non-carriers. 
Finally, the rs852977, rs10482633, rs10052957 polymorphisms were 
associated with AD response in the STAR*D sample, although none 
of them survived after correction for hypothesis-wide effective 
number of comparisons (Uher et al., 2009).
c-amP resPonse-element bIndIng
An increasing number of studies recently focused on the role of the 
c-AMP response-element binding (CREB) protein in MDD. As a 
matter of fact, several studies found a role of CREB both in the eti-
ology and pharmacotherapy of MDD (Sulser, 2002; Blendy, 2006). 
CREB1 has also been found to be associated with AD response in 
depressed patients (Wilkie et al., 2007) and with lithium response 
in patients with bipolar disorder (CREB1-1H and CREB1-7H 
SNPs; Mamdani et al., 2008). Further, rs4675690, a SNP located 
at the 5′ of CREB1, was found to have a role in suicidal behaviors in 
patients with MD (Perlis et al., 2007b) and, along with rs7569963, 
to be associated with anger expression in men suffering from MD 
(Perlis et al., 2007a). Despite some negative results (Burcescu et al., 
2005; Hettema et al., 2009), current evidence suggests that CREB1 
could play an important role both in the development of MDD and 
related features as well as in the ADs response like showed in several 
studies on animal models (Thome et al., 2000; Kuipers et al., 2006; 
Tardito et al., 2006; Boer et al., 2010). The CREB1 polymorphisms 
are still poorly investigated in the field of pharmacogenetic of 
AD response, resistance and remission. Dong et al. (2009), like 
Wilkie et al. (2007), failed to find any association between several 
CREB polymorphisms and AD response, although they showed a 
significant association between one SNP (rs3730276) and MDD. 
Recently, Serretti et al. (2011) suggested that some alleles or hap-
lotypes within CREB1 could be related to treatment resistance but 
not to response and remission to current AD treatment as well 
as to a diagnosis of MD. Finally, Perlis et al. (2007a) suggested a 
role of genetic variants within CREB gene on treatment-emergent 
suicidal ideation during citalopram treatment. Interestingly they 
found significant associations only in men, suggesting a significant 
gene × sex interaction.
braIn-derIved neurotroPhIc Factor
Brain-derived neurotrophic factor, a member of the neurotrophin 
family of survival-promoting molecules, plays an important role 
in the growth, development, maintenance, and function of several 
neuronal systems (Acheson et al., 1995). There is growing evidence 
that BDNF can be relevant in mood disorders and that modula-
tion of its biosynthesis following prolonged AD treatment may 
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contribute to neuroplastic changes required for clinical response 
(Calabrese et al., 2007; Reagan et al., 2007). There are several stud-
ies that suggested a role of the BDNF in the mechanism of action 
of AD drugs (Conti et al., 2007; Rogoz et al., 2007). The reported 
increase in BDNF mRNA expression after AD treatment is a corner-
stone of the BDNF hypothesis of AD action (Jacobsen and Mork, 
2004). Several evidences support an influence of BDNF polymor-
phisms in AD response. In this regard, the most investigated SNP 
within this gene is rs6265 which results in a valine to methionine 
(V66M) substitution (Egan et al., 2003). Nonetheless results are 
still controversial (Wilkie et al., 2007; Rajewska-Rager et al., 2008; 
Kang et al., 2009). While some authors found a better outcome for 
the heterozygote genotype (Yoshida et al., 2007) or a trend in this 
direction (Tsai et al., 2003; Zou et al., 2010a), on the other hand 
other studies showed an association between Val/Val genotype and 
better outcome (Mandelli et al., 2010; Zou et al., 2010b). Moreover, 
several studies reported Met allele associated with better response 
(Choi et al., 2006; Licinio et al., 2009), and with lower fluoxetine side 
effects (Zou et al., 2010a). Rs6265 was also associated with the pres-
ence of stressful life events prior to the depression onset (Bukh et al., 
2009), although this result was not confirmed in a further study 
by the same authors (Bukh et al., 2010). Also rs90887, rs61888800, 
rs7124442, and rs11030104 SNPs within BDNF gene have been asso-
ciated with AD response (Gratacos et al., 2008; Licinio et al., 2009; 
Domschke et al., 2010; Mandelli et al., 2010) A strong association 
was found between rs962369 and an increase in suicidal ideation 
during AD treatment (Perroud et al., 2009). Finally, it is interest-
ing to note that significant associations between some variants in 
neurotrophic tyrosine kinase, receptor, type 2 gene (NTRK2) – that 
encode the BDNF receptor – (rs2289657, rs56142442, rs2289658, 
rs2289657, and rs2289656) and AD response have been found in 
Mexican-Americans (Dong et al., 2009).
other gene varIants
Besides those described, there are many genes that may influence both 
the onset and evolution of MDD, and the effects of AD pharmacotreat-
ment, among these noteworthy are: the ACE (Baghai et al., 2001, 2003, 
2004; Bondy et al., 2005), the CLOCK gene (Benedetti et al., 2003a; 
Serretti et al., 2003a, 2005b), the glutamatergic system (Laje et al., 
2007, 2009; Paddock et al., 2007; Perlis et al., 2009b; Tsunoka et al., 
2009; Horstmann et al., 2010), NOS (Paul, 2001; Suzuki et al., 2003; 
Wegener et al., 2003; Okumura et al., 2010), and IL-1B (Yu et al., 2003; 
Tadic et al., 2008; Baune et al., 2010; Uher et al., 2010).
genome-wIde assocIatIon studIes
A genome-wide association study (GWAS) is an approach that 
involves rapidly scanning markers across the complete sets of DNA, 
or genomes, of many people to find genetic variations associated with 
a particular disease. This innovative method seems particularly useful 
to study complex diseases, such as psychiatric disorders. One of the 
limits of this methodology is the risk of false positive results. Even if 
in AD pharmacogenetics, the number of GWAS performed is limited 
and results need replication, unbiased approaches using genome-
wide gene expression or association results could lead to important 
advances in this field. Recently, GWAS were performed within the 
GENDEP project and the STAR*D (Craddock et al., 2009; Garriock 
and Hamilton, 2009; Ising et al., 2009; Laje et al., 2009; Perroud et al., 
2010). One of the major limits of GWAS is the incapacity to detect 
rare genetic variants (<1% of the population). Indeed, current GWAS 
technologies are able to detect only association for genetic variants 
present in 5% or more of the population (Craddock et al., 2009). 
The results reached by GWAS, to date, have been disappointing. For 
this reason large meta-analysis to reach genome-wide significance 
are often needed (McCarthy and Hirschhorn, 2008).
conclusIon
The synopsis of pharmacogenetic studies indicates several strong 
candidate genes involved in AD response. Nonetheless, the lack of 
standardized study design renders meta-analyses as well as compar-
isons across studies difficult. Several factors can influence the results 
that often are conflicting: inclusion criteria, medication, outcome 
and side effect measures, ethnicity, and genetic coverage. Given the 
complex nature of the biology of AD treatment response and the 
relevance of environmental factors, such as repeated treatment, 
number of episodes or the occurrence of life events, the addition 
of non-genetic markers for optimal treatment prediction will likely 
be necessary (Holsboer, 2008). There is great hope that the field 
of pharmacogenomics will offer personalized medicine treatments 
based on genetic profiles and in this way may have the potential to 
offer many benefits for further therapeutic approaches.
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